Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab plus first-line antiretroviral therapy in treatment-naive adults with HIV-1
2018-000497-30Phase 2Completed
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Mar 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of vedolizumab, dolutegravir, emtricitabine and tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Adverse events and their degree. Started Mar 2018; status: completed.
02
Drugs
vedolizumabdolutegraviremtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2018-000497-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000497-30.